Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
anticonvulsant/hypoxie
Le lien est enregistré dans le presse-papiers
9 résultats
4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula
##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically
Benzathiazol-acetamides
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
Benzothiazole derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
Adenosine receptor ligands and their use in the treatment of disease
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention is generally related to compounds useful as adenosine receptor ligand and more particularly to compounds showing activity as modulators of the andenosine receptor system.
BACKGROUND OF THE INVENTION
Several compounds related to general formula I have been
Use of conantokins
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which include preferably one to two or more
Use of conantokins
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturaly available peptides, and which include preferably one to two or more
Dibenz[b,e]oxepin derivatives and pharmaceutical composition containing the same
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FEATURES OF THE INVENTION
The present invention relates to novel dibenz[b,e]oxepin derivatives useful for prevention and treatment of cerebral diseases caused by hypoxia.
TECHNICAL BACKGROUND
The brain, different from other organs, exists under particular environment such that it is dipped in
Thiophene derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This invention relates to novel and therapeutically valuable compounds of the formula ##SPC2##
And pharmaceutically acceptable acid addition salts thereof. In the above formula, R.sup.1 is H or CH.sub.3 ; R.sup.2 is CH.sub.3 or C.sub.2 H.sub.5, or R.sup.1 and R.sup.2 combinedly represent
Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
NMDA AMPA Receptors
Excessive excitation by neurotransmitters can cause the degeneration and death of neurons. It is believed that this degeneration is in part mediated by the excitotoxic actions of the excitotoxic amino acids (EAA) glutamate and aspartate at the
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
